CERE News and Press, Ceres Inc. From 02/22/23

Cerevel Therapeutics Holdings, Inc. (CERE) Q4 2022 Earnings Conference Call February 22, 2023 08:00 ET Company Participants Matt Calistri - Vice President of Corporate Strategy & Investor Relations Anthony Coles - Chairperson & Chief Executive Officer Raymond S...

Cerevel Therapeutics ( NASDAQ: CERE ) lost ~14% on Wednesday, marking the steepest selloff since August after neuroscience-focused biotech pushed back the timeline for multiple clinical programs with its Q4 2022 results. Citing lower-than-expected patient enrollment due to the pos...

Cerevel Therapeutics press release ( NASDAQ: CERE ): Q4 GAAP EPS of -$0.59 beats by $0.05 . Cash, cash equivalents and marketable securities as of December 31, 2022, were $950.2 million, compared to $618.0 million as of December 31, 2021. For further details see: Cer...

Emraclidine Phase 1 healthy elderly volunteer trial enrollment underway to support development in Alzheimer’s disease psychosis Emraclidine Phase 2 schizophrenia data readout remains on track for 1H 2024 Clinical trial timeline updates provided for additional lead program...

CAMBRIDGE, Mass., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report fourth quarter and full year 2022 financial results and business ...

Initiated Phase 1 healthy volunteer trial to support development of emraclidine in Alzheimer’s disease psychosis in Q4 2022; second potential indication as a once-daily treatment Phase 2 proof-of-concept darigabat panic disorder trial to be initiated in Q2 2023 Multiple d...

CAMBRIDGE, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics , (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that chairperson and chief executive officer Tony Coles, M.D., will present at the upcoming 4...

Data provide clear evidence that emraclidine does not induce an increase in blood pressure with chronic dosing in people living with schizophrenia Emraclidine demonstrated a mean change from baseline in 24-hour ambulatory systolic blood pressure at week eight of -2.7 mmHg for 10 mg QD a...

Emraclidine is being developed as a potential once-daily treatment for schizophrenia without the need for titration Data show clinically meaningful and statistically significant improvement with emraclidine in PANSS total score at six weeks and was overall well-tolerated compared with p...

The following slide deck was published by Cerevel Therapeutics Holdings, Inc. in conjunction with their 2022 Q3 earnings call. For further details see: Cerevel Therapeutics Holdings, Inc. 2022 Q3 - Results - Earnings Call Presentation